Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

98.050
+2.1502.24%
Volume:16.81M
Turnover:1.64B
Market Cap:171.10B
PE:208.62
High:99.350
Open:95.150
Low:94.800
Close:95.900
52wk High:112.700
52wk Low:69.550
Shares:1.75B
HK Float Shares:1.75B
Volume Ratio:1.98
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.470
ROE:7.01%
ROA:2.23%
PB:7.06
PE(LYR):208.62
PS:9.32

Loading ...

Obesity Specialty Standardized Weight Management Service System Initiative Launches in China

Deep News
·
Jul 26

Movement Alert|Innovent Biologics Rises 3.04% in Regular Trading, BD Deal Catalyst and Biotech Sector Recovery Drive Gains

Market Focus
·
Jul 20

Movement Alert|Innovent Biologics Falls 3.45% in Regular Trading, Trading at HK$89.85

Market Focus
·
Jul 17

Innovent Biologics (SEHK:1801) Is Up 9.1% After Striking US$1.10 Billion IBI355 Licensing Deal

Simply Wall St.
·
Jul 16

CLSA Raises Innovent Biologics Price Target to HK$139.9, Citing New Overseas Partnership

Stock News
·
Jul 16

Movement Alert|Innovent Biologics Falls 3.09% in Regular Trading, Trading at 94.4 HKD

Market Focus
·
Jul 16

Hong Kong Market Analysis: Longxun's IPO Valuation Sets Benchmark, Stirring Tech Sector; "Lab Monkey" Prices Drive CXO Surge

Stock News
·
Jul 15

Hong Kong Market Rises 1.4% on Fed Policy Shift Hopes; Healthcare and Consumer Stocks Lead Gains

Stock News
·
Jul 15

Innovent Biologics Shares Surge on Spero Deal That Could be Worth $1.1 Bln

Dow Jones
·
Jul 15

Innovative Drug Stocks Surge Following Inclusion in National Essential Medicines List, Accelerating Grassroots Access

Stock News
·
Jul 15

Innovent Biologics Shares Rise Over 3% on Exclusive Licensing Deal for IBI355 and Upcoming SjD Phase II Study

Stock News
·
Jul 15

Movement Alert|Innovent Biologics Rises 3.78% in Regular Trading, Exclusive Licensing Agreement with Spero Therapeutics for Third-Generation Anti-CD40L Antibody

Market Focus
·
Jul 15

Spero Licenses Innovent's Experimental Immune Disease Drug for up to $1.1 Billion

Reuters
·
Jul 14

Innovent Biologics Licenses Anti-cd40l Antibody Ibi355 to Spero in Deal Worth About USD 1.1 Billion

Reuters
·
Jul 14

Spero Therapeutics - Innovent to Receive Payments Totaling About $1.1 Bln Plus Tiered Royalties

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - Innovent to Initiate Phase 2 Trial for Sjögren’s Disease in China by Early 2027

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - to Initiate Phase 2 Trial for SP001 in Igg4-rd in Q2 2027

THOMSON REUTERS
·
Jul 14

Innovent Biologics - Spero Receives Exclusive Global Rights to Ibi355 Excluding Greater China

THOMSON REUTERS
·
Jul 14

Innovent Biologics and Spero Therapeutics Announce Exclusive License for Ibi355 (sp001), a Phase 2-ready Third-generation Anti-cd40l Antibody

THOMSON REUTERS
·
Jul 14

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

GlobeNewswire
·
Jul 14